Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ThromboGenics
ClinicalTrials.gov Identifier:
NCT00123305
First received: July 21, 2005
Last updated: April 4, 2014
Last verified: April 2014
  Purpose

The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.


Condition Intervention Phase
Stroke, Acute
Drug: Microplasmin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre, Double-Blind, Placebo-Controlled, Ascending-dose, Clinical Trial of Intravenous Microplasmin Administration in Patients With Acute Ischemic Stroke

Resource links provided by NLM:


Further study details as provided by ThromboGenics:

Primary Outcome Measures:
  • Intracranial haemorrhage [ Time Frame: 24 hours and Day-7 ] [ Designated as safety issue: Yes ]
  • Change from Baseline in NIHSS [ Time Frame: Day7 and Day-90 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Barthel Index and modified Rankin scale [ Time Frame: Day-90 ] [ Designated as safety issue: No ]
  • Markers of systemic lysis [ Time Frame: Baseline, end of treatment, 6, 12, 24, 72 and 96 hours ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: October 2005
Study Completion Date: June 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Microplasmin
1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
Experimental: 2 Drug: Microplasmin
1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
Experimental: 3 Drug: Microplasmin
1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
Placebo Comparator: 4 Drug: Microplasmin
1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution

Detailed Description:

While the primary objective of the trial is safety evaluation, efficacy assessments will also be obtained, including MRI/MRA (including DWI, PWI and T2 imaging) and plasma surrogate biomarkers. Clinical outcome will also be assessed at 7days, 30 days and 90 days post-treatment. At each of these visits, mortality and neurological assessments (NIHSS, Barthel index, mRankin scale) will be performed. In addition, vital status will be assessed vial a telephone contact at 60 days post-treatment.

The trial will investigate three dose regimens of microplasmin, all of which are within the range of doses previously evaluated in a Phase I trial in healthy volunteers; the planned sample size for the trial is approximately 40 patients.

The study will consist of 3 phases - the Baseline, In-hospital Phase and Follow up Phase. Baseline is from study entry through randomisation; the In-hospital phase is from treatment with study drug through hospital discharge or day 7, whichever occurs first. The follow up phase consists of visits to the hospital 30 days (+ 3 days) from the day of study drug administration. Hospital discharge is defined as the end of the discharge from the acute hospital setting. Discharge may be to home, to a rehabilitation setting or to a non-acute hospital setting.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute ischemic stroke with onset within 12 hours before randomization with baseline NIHSS > 6 and < 22

Exclusion Criteria:

General Exclusion Criteria

  • Participation in another study with an investigational drug or device within the previous 30 days, prior participation in the present study, or planned participation in another trial within the time frame of the current trial
  • Symptoms suggestive of subarachnoid hemorrhage, even if CT scan or MRI is negative for hemorrhage
  • Women known to be pregnant, lactating, or having a positive or indeterminate pregnancy test

Stroke Related Exclusion Criteria

  • Neurological deficit that has led to stupor or coma (National Institutes of Health Stroke Scale [NIHSS] Level Of Consciousness Item 1a score >or=2)
  • High clinical suspicion of septic embolus
  • Thrombosis involving cerebral veins
  • Rapidly improving neurological signs at any time before initiation of study drug administration

Imaging Related Exclusion Criteria

  • Hemorrhagic transformation or intracerebral hemorrhage observed on baseline CT of the brain or gradient recalled echo (GRE) magnetic resonance imaging
  • CT or MRI evidence of nonvascular cause for the neurological symptoms
  • Large hypodensity on CT involving > 1/3 of the middle cerebral artery (MCA) territory
  • Baseline DWI volume > 1/3 of the MCA territory
  • Signs of mass effect causing shift of midline structures on CT or MRI
  • Unable to undergo MRI (i.e., ferrous implants, cardiac pacemakers, agitation, claustrophobia or known sensitivity to MRI contrast agents)

Safety Related Exclusion Criteria

  • Congenital or acquired coagulopathy causing either of the following

    1. activated partial thromboplastin time prolongation greater than 2 seconds above the upper limit of normal (ULN) for local laboratory
    2. International normalized ratio (INR) of 1.4 or more.
  • Uncontrolled hypertension defined as a systolic blood pressure > 180 mm Hg or a diastolic blood pressure > 100 mm Hg on 3 separate occasions at least 10 minutes apart or requiring continuous intravenous (IV) therapy.
  • History of stroke within the previous 3 months
  • Seizures at any time between stroke onset to planned initiation of study drug
  • History of intracranial hemorrhage
  • History of surgery, lumbar puncture, biopsy or trauma to internal organs within the previous 30 days.
  • Major trauma at the time of stroke
  • Head trauma within the previous 90 days.
  • Known bleeding diathesis.
  • Baseline platelet count < 100 X 10^9/L.
  • Blood glucose > 400mg/dl or <50 mg/dl if administration of glucose does not rapidly reverse neurological deficit

Exclusion Criteria That May Potentially Interfere with Outcome Assessment

  • Life expectancy <3 months
  • Other serious illness that in the opinion of the investigator may confound clinical assessment (e.g. hepatic, cardiac, or renal failure, advanced cancer)

Exclusion Criteria Related to Concomitant Medication

  • If treatment with tPA is indicated
  • Treatment with rtPA or any other thrombolytic agent for the qualifying stroke
  • Administration of intra-arterial or systemic thrombolytic therapy in previous 7 days
  • Need for antiplatelet agent, unfractionated or heparin-related products, direct thrombin inhibitor, oral anticoagulant within 24 hours after treatment bolus.
  • Treatment with low molecular weight heparin, direct thrombin inhibitor, or GPIIb/IIIa antagonists within 48 hours prior to randomisation
  • Treatment with vitamin-K antagonists or heparin (or heparin-related compounds) which results in either an INR>1.4 or an aPTT>2 times control (ULN for the hospital laboratory)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00123305

Locations
Austria
Universitatsklinik fur Neurologie
Graz, Austria, 8036
Landesnervenklinik Wagner-Jauregg
Linz, Austria, 4020
AKH Linz Neurolog Abt
Linz, Austria, A-4020
Allgemeines Offentliches Krankenhaus der
Linz, Austria, A-4021
Belgium
Cliniques Universitaires St Luc
Brussels, Belgium, 1200
Gasthuisburg Hospital
Leuven, Belgium, B-3000
Germany
Universitätsklinikum Erlangen
Erlangen, Germany, 91054
Universitatsklinikum Essen
Essen, Germany, 45122
Klinikum der J.W Goethe Univeristy
Frankfurt, Germany, 60528
Universitatsklinikum Freiburg
Freiburg, Germany, 79106
Georg August Universitat Gottingen
Gottingen, Germany, 37075
Universitatskrankenhaus Hamburg-Eppendorf
Hamburg, Germany, 20246
Universitatsklinikum Leipzig
Leipzig, Germany, 04103
Klinikum Minden, Chefarzt der Neurologischen Klinik
Minden, Germany, 32427
Klinikum rechts der Isar der TU München
München, Germany, 81675
HSK Dr. Horst Schmidt Hospital
Wiesbaden, Germany, 65199
Sponsors and Collaborators
ThromboGenics
Investigators
Principal Investigator: Vincent Thijs, MD PhD KU Leuven
  More Information

No publications provided

Responsible Party: ThromboGenics
ClinicalTrials.gov Identifier: NCT00123305     History of Changes
Other Study ID Numbers: TG-M-04
Study First Received: July 21, 2005
Last Updated: April 4, 2014
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
Belgium: Institutional Review Board
France: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by ThromboGenics:
Stroke
Acute Ischemic Stroke

Additional relevant MeSH terms:
Stroke
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia

ClinicalTrials.gov processed this record on August 20, 2014